District Party Secretary Min Wang paying a visit to the China Australia Medical Innovation Park: An in-depth display of the “AI + health sciences” sector ecosystem

On the 22^nd of July, Secretary of the District Party Committee Min Wang, along with Deputy District Mayor Feng Tao, led a delegation to the China Australia Medical Innovation Park to specifically visit METiS Hangzhou Jitai Pharmaceutical Technology Co., Ltd. and Yizun Biomedical (Zhejiang) Co., Ltd.

Secretary Wang was welcomed into METiS Pharmaceutical and given a run-down on the recent results achieved by the company, which were obtained by utilizing specific artificial intelligence technology incorporated into their novel drugs research and development regime. The company CEO further explained that his vision for the near future would be to establish a viable ecosystem, and to collaborate with more pharmaceutical companies to assist them in achieving meaningful operational evolution. This vision was met with much approval and affirmation by Secretary Wang.

At Yizun Biomedical, Secretary Wang had an in-depth discussion with the company’s managing director to get a better understanding of their current operational and R&D situation, the advantages that they possess in the form of a technology platform for innovative cell therapy, before proceeding to take a tour of the cell culture laboratory.

As highlighted by Secretary Wang, in recent years, the Binjiang High-tech Zone has laid extremely robust foundations and provided huge backing to enable the flourishing of the digital industry, astutely integrating digital technology and the digital economy with the health sciences sector, thereby achieving the status of a leading region in the fields of medical devices, life sciences and e-health.

However, Secretary Wang was at pains to emphasize that the mission is not complete, that in the ensuing future, there should be enhanced collaboration between industry and academia, to engender an improved environment that encourages innovation, and for the systems to be in place that enhances commercialization of innovation.

With such an ecosystem established, it will further enhance the High-tech Zone’s reputation as the premier destination for health sciences companies, which in turn will promote a virtuous cycle of injecting more vitality into this industry in the Binjiang district.

Official Source:

Binjiang District Press Release

METiS Hangzhou Jitai Pharmaceutical Technology Co., Ltd.

METiS Hangzhou Jitai Pharmaceuticals is the world's first artificial intelligence-driven pharmaceutical preparation development of new companies, the team combined with high-throughput preparation platform and artificial intelligence computing technology, for pharmaceutical companies to provide fast and accurate intelligent preparation research and development. METiS Pharmaceuticals is a top team of Chinese and American scientists from the American Academy of Engineering and several MIT scientists, with unique experience in clinical trials and FDA approval, in addition to high-end formulation research and development technology. The team invested millions of dollars by Fengrui and Source Capital to develop new drugs for cancer, infectious diseases, etc., to bring high-quality and efficient drugs to patients.

Yizun Biomedical (Zhejiang) Co., Ltd.

Yizun Biomedical (Zhejiang) Co., Ltd. is a cutting-edge immune cell therapy company with several global original platform technologies, featuring the application of general-purpose technologies for solid tumor therapy and allogeneic cells. At present, the company has developed three core technology platforms with completely independent intellectual property rights and industry leadership and has achieved technological breakthroughs and leadership in several fields of cell therapy. Since establishing headquarters at the China Australia Medical Innovation Park, the company has actively integrated into the ecosystem. It has not only established strategic partnerships with industry heavyweights but will also accelerate the clinical transformation of technology through technical collaboration and licensing models.

China Australia Medical Innovation Park (CAMIP)

The China Australia Medical Innovation Park (CAMIP) was established as a collaborative partnership between Hangzhou’s High-tech Zone (in Binjiang) and China’s Torch Center, with significant support from China’s Ministry of Science and Technology. The Park is managed by China’s pre-eminent health sciences commercialization entity, Bioclub. CAMIP’s mandate is to establish a co-operative framework with key institutions in the fields of medical technology, biologics and the broader life sciences umbrella both domestically and overseas, with Australia being a key regional focus. A key focus area of ours is to assist entrepreneurs in accelerating and successfully commercializing their research and innovative technology.